Announcement PDF ABN 16 165 160 841 ASX RELEASE 30 May 2023 Annual Report – Year Ended 31 March 2023 Amplia Therapeutics Limited (ASX: ATX) today releases its Annual Report – Year Ended 31 March 2023 (incorporating its Appendix 4E Preliminary Final Report YE 31 March 2023) This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. - End Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn. Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com ANNUAL REPORT 1 FIGHT C 2022-2023 Amplia Therapeutics Ltd Amplia Therapeutics recognises and respects First Nations People and welcomes the work of all those who strive for health equality in Australia. 2 Contents Letter from the Chairman ..................................................... 4 CEO’s Message ...................................................................... 6 Meet the Team ................................................................... 8 Company Snapshot ......................................................... 10 Review of Operations ...................................................... 13 Clinical Trials - bright minds, steady hands .................. 14 News Flow and Milestones .................................................. 16 Q&A with Dr Chris Burns, MD & CEO ..................................... 18 Advancing Amplia’s Preclinical Program ...................................... 20 Our Values ................................................................................................... 22 Financial Report .................................................................................................... 23 Letter from the Chairman Dear Shareholders, On behalf of your Board it is my pleasure to share with you the 2023 Annual Report of our Company. This has been an important year for Amplia. Firstly, and most importantly, with the COVID pandemic largely behind us we were able to move forward freely with our Phase 1b/2a trial of AMP945 in pancreatic cancer (the ACCENT trial) and begin dosing patients. As I write this we are well into the dose range-finding stage of the study with the third cohort completely enrolled. Initially recruitment into the study was slowed through some delays at clinical sites as they dealt with COVID related staff shortages. Recruitment is now back on track and we are grateful for the coordinated efforts of sites and the team of people managing the study. The progress in the ACCENT trial is a credit to both Dr John Lambert, our inaugural CEO, and to Dr Chris Burns, who was appointed as CEO and Managing Director in December 2022. We had high expectations that this change of leadership would go very smoothly and those expectations have been justified. We thank John for his leadership and sterling efforts in building the Company and establishing the clinical program for AMP945. Chris Burns, as a fellow Board member and co-founder of the Company, was very well placed to takeover this leadership role. In addition to driving the ACCENT trial, Chris has been active in exploring additional opportunities for our FAK inhibitors through preclinical studies, and progress from these will be reported in due course. Dr Terrie-Anne Cock, Head of Translational Biology, also joined the Company in the last year (see page 21) and brings a wealth of invaluable experience in drug development. This promising progress for Amplia is taking place in an environment where biotechnology companies in Australia, and indeed around the world, are facing significant headwinds at present. Market sentiment is poor, capital markets have shrunk, and as a consequence, deals (collaborations, partnerships, acquisitions) with pharma and larger biotechs are down compared to historical norms. Nevertheless, the Company remains confident that our developing dataset, both clinical and preclinical, for our FAK inhibitors continues to add value to the Company and enhance shareholder value as well as increase opportunities for commercial deal-making going forward. Dr Burns is well established in his new role as CEO and making significant contributions to Amplia. Progress over recent months reflects his leadership of our small, experienced, and cohesive management team. I am grateful for the significant contributions and guidance of my fellow Directors. The Board’s collegial approach and ‘roll-up-the sleeves’ attitude has undoubtedly added to the Company’s success. In conclusion, Amplia continues to make excellent progress with the ACCENT trial while exploring additional value-creating opportunities for our FAK inhibitors. Warwick Tong Independent Non-Executive Chair 4 “ We are resolutely focused on ethical drug development – and the next 12-18 months will be a defining chapter in our journey to improve the lives of people with pancreatic cancer. NON-EXECUTIVE CHAIRMAN, WARWICK TONG CEO’s Message This past year has been a significant one for Amplia as we initiated our first clinical trial in patients. The ACCENT trial in advanced pancreatic cancer patients was approved by Human Research Ethics Committees in April and May 2022, and the first patient was dosed in early August 2022. We now have seven sites open across Melbourne, Sydney and Brisbane and the pace of recruitment has now substantially improved after a slow start impacted by lingering COVID constraints. This trial is in two stages: the first stage (Phase 1b) is a dose-range finding stage where increasing doses of AMP945 are tested in cohorts of three patients to assess safety, tolerability and PK/PD* effects; the second stage (Phase 2a) is directed towards testing the best dose identified from the Phase 1b portion in up to 50 patients and assessing for signs of clinical efficacy. Over the course of this financial year, we successfully completed dosing two cohorts in the Phase 1b portion of the trial. Looking forward, we anticipate completing the Phase 1b portion of the trial in the third quarter of the year and starting the Phase 2a component of the trial before year end. In the background the Amplia team have been expanding the formal preclinical work on AMP945 to allow for regulatory filings with the Korean and US drug regulators to enable expansion of the trial to these countries. In particular, our goal is to open sites in Korea later this year so that these sites can participate in the Phase 2a portion of the trial. Also noteworthy is that chemical synthesis of the drug on scale has progressed smoothly, as has manufacture of the final capsule form for use in the trial. We have continued to explore additional clinical opportunities for our FAK assets AMP945 and AMP886 across a range of disease indications. Studies undertaken over the year with AMP945 for the debilitating lung disease idiopathic pulmonary fibrosis (IPF) demonstrated that the compound performs as well as the current standard-of-care drug nintedanib in a preclinical model of the disease. This result is extremely promising given that the annual sales for nintedanib are >US$2b despite it being poorly tolerated by patients. Our IND-enabling studies with AMP945 in IPF are continuing. We routinely review the scientific literature for research identifying FAK’s role in disease, and where a FAK inhibitor may be a potential treatment option. A number of preliminary laboratory studies have been initiated with AMP945 over the year, and findings will be reported once the studies are complete. In addition, we have trialled our second FAK inhibitor, AMP886, in specific mouse models of acute myeloid leukemia (AML), a poorly treated blood cancer. Our data clearly demonstrated that AMP886 reduced disease burden in treated animals in a dose-dependent manner and further studies are underway to explore the competitive potential of AMP886 in this indication, compared with opportunities for this compound in solid tumours. This year also saw a change of leadership at Amplia Therapeutics, with the departure of Dr John Lambert and my appointment. I am extremely grateful to the Board for giving me the opportunity to lead the Company at this exciting time and ensuring that the transition proceeded smoothly. I would personally like to thank John for his assistance in the transition and for building such an exceptional group of co-workers at the Company. The team at Amplia is top-notch and the uninterrupted progress across our manifold activities is testament to this. Everything we do at Amplia is made possible by the support of our shareholders and investors. We remain focused on increasing shareholder value by progressing our programs in the most capital-efficient manner, to address serious unmet medical needs. Dr Christopher Burns CEO & MD *PK/PD = pharmacokinetics and pharmacodynamics 6 “ Our primary goal is to advance the development of AMP945 in pancreatic cancer by completing the ACCENT trial, and moving towards registration enabling trials in Australia, the US and Europe. CEO & MD, DR CHRISTOPHER BURNS Meet the Team Board of Directors WARWICK TONG MB ChB MPP GAICD Non-Executive Chairman of the Board Warwick is a NZ trained physician with more than 25 years’ experience in the pharmaceutical and biotechnology industry. Dr Tong was appointed as a Non-Executive Director on 4th of May 2018 and Chairman on 25th May 2018. Dr Tong is also a member of the Audit Committee. CHRISTOPHER BURNS B.Sc. (Hons) PhD GAICD Chief Executive Officer and Managing Director Chris is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 30 years. Dr Burns was originally appointed as a Non-Executive Director on 4th May 2018 and was subsequently appointed as Chief Executive Officer and Managing Director on 5th December 2022. ROBERT PEACH PhD Independent Non-Executive Director Robert has over 25 years of drug discovery and development experience in the pharmaceutical and biotechnology industry. Dr Peach was appointed as an Independent Non-Executive Director on 2nd of September 2015 and is a member of the Remuneration Committee. JANE BELL BEc, LLB, LLM (Lond), FAICD Independent Non-Executive Director Jane is a banking and finance lawyer and non-executive director with more than 30 years’ experience in leading law firms, financial services and corporate treasury operations in Melbourne, London, Toronto, San Francisco and Brisbane. Ms Bell was appointed as an Independent Non-Executive Director on 12th April 2021 and is Chair of the Audit and Risk Committee. 8 Meet the Team Executive Team Scientific Advisers CHRISTOPHER BURNS BSc (Hons) PhD, GAICD Chief Executive Officer and Managing Director PROFESSOR MARGARET FRAME OBE, PhD FAK Biology Adviser RHIANNON JONES BSc (Hons) PhD, GAICD PROFESSOR PAUL TIMPSON PhD Chief Operating Officer FAK Biology Adviser HAMISH GEORGE CA, BCom, GIA(Cert) DR MARK DEVLIN BSc (Hons) PhD GradD Drug Dev MBA Chief Financial Officer Scientific Adviser ANDREW J. COOKE LL.B DR JULIE BULLOCK PhD Company Secretary Clinical Pharmacology Consultant CHARLOTTE MULDER BVSc (Hons), MBA Principal Development Manager ANTHONY BISHOP BSc, GradDip Principal Development Manager TERRIE-ANNE COCK PhD Head of Translational Biology ADRIAN SULISTIO B Eng (Hons), B. Com, PhD CMC Project Manager NICOLE KRUGER BSc Clinical Operations Manager Clinical Advisers DR JOSE IGLESIAS MD Clinical Adviser (Oncology) DR JASON LICKLITER MBBS, FRACP Medical Adviser Company Snapshot The team is developing two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK), which show promise in treating cancer and fibrotic diseases. Amplia is a drug development company focused on new treatments for cancer and fibrotic diseases. The lead compound, AMP945, is currently being studied in a Phase 1b/2a clinical trial for advanced pancreatic cancer, in combination with standard-of-care chemotherapy gemcitabine and nab-paclitaxel, in Australia. A Phase 1 clinical trial of AMP945 in healthy volunteers was successfully completed in 2021. Australian Innovation Amplia’s lead drug candidates, AMP945 and AMP886, were both discovered in Melbourne, Australia by researchers at the Cancer Therapeutics CRC – a successful cancer research collaboration between Australia’s leading research institutes, universities, and biotechnology companies. Recognising the potential of both molecules, the Company proudly brought this promising technology from the lab, into clinical development. Following a successful Phase 1 trial in healthy volunteers, the Company is now conducting the ACCENT trial, a Phase 1b/2a clinical trial of AMP945 in first line pancreatic cancer patients across seven clinical sites in Melbourne, Sydney and Brisbane. Targeting Focal Adhesion Kinase Focal Adhesion Kinase (FAK) inhibitors are a promising area of cancer research. FAK is an increasingly important target in cancer and particularly cancers that generate a protective fibrotic and immunosuppressive microenvironment around the tumour cells. At this stage of its development, Amplia is targeting resources on fibrotic cancers, of which pancreatic cancer is one of the most deadly. By targeting FAK, we have the potential to disrupt these fibrotic and immunosuppressive pathways and slow the progression of cancer. Additionally, FAK inhibitors have shown promise in treating other fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), which opens up an alternate area of therapeutic potential for Amplia’s pipeline drugs. 10 AMP945 Lead candidate, AMP945, is a highly selective and potent FAK inhibitor that has shown promising results in preclinical studies for the treatment of pancreatic cancer. Pancreatic cancer is a difficult to treat cancer, with a low survival rate – only 3 out of 10 people (35.5%) will survive one year after diagnosis of pancreatic cancer1. Fibrotic shields protect many solid tumours from chemotherapy. Amplia’s FAK inhibitors aim to remove this shield, making the tumours more susceptible to chemotherapy. In preclinical models of other (non-cancer) fibrotic diseases, the efficacy of AMP945 has been shown to be similar to or better than current standard-of-care therapies. FAK inhibitor Fibrotic tumour microenvironment (FAK) Exposed tumour Dead tumour Created with BioRender.com Amplia’s ACCENT trial is a multicentre, open label, two-part study to determine whether AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to chemotherapy in first-line patients with unresectable or metastatic pancreatic cancer. Recruitment is now underway. AMP886 AMP886 is also a highly potent FAK inhibitor, that also inhibits two other validated disease targets. Preclinical studies suggest AMP886 may have clinical potential in the treatment of acute myeloid leukemia (AML) and certain solid tumours. 1 Australian Institute of Health and Welfare (2022) https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia 11 Pipeline Amplia continues to explore the potential of both AMP945 and AMP886 in a range of preclinical models of cancer and fibrotic disease to identify future development, partnering, and licensing opportunities. The current development pipeline is strong. Current Status Next 12 Months Drug Indication Therapy AMP945 Pancreatic Cancer Combination Therapy AMP945 Idiopathic pulmonary fibrosis (IPF) Monotherapy AMP945 Cancers and fibrotic disease Combo/ Monotherapies AMP886 Cancers and fibrotic disease Combo/ Monotherapy Preclinical Phase 1 Phase 2 Phase 3 (approval) Established Networks Amplia has built strong connections with highly respected clinicians and researchers within the oncology community – both in Australia and worldwide. These experts provide valuable insight into the development of its therapies and help guide clinical trial strategies. In addition, the Company has built a network of respected drug development advisers, contract research organisations and clinical operations specialists so that our trials are conducted efficiently and to world’s best practice. 12 Review of Operations The Road Ahead Amplia is constantly exploring new ways to collaborate, innovate, and deliver life-changing outcomes for patients around the world. As a values-driven company, Amplia is motivated to build a better future for our team, collaborating stakeholders, and the wider community. Robust plans are in place to safeguard the Company’s long-term growth and sustainability. While the focus continues to be on advancing Amplia’s lead asset AMP945 through the clinic via the ACCENT trial in pancreatic cancer, there are clear plans to maximise the potential of the FAK inhibitor development program in other cancers and fibrotic diseases too. Amplia is also investing in its team and infrastructure to sustainably support its operations. Strategic Planning The goal is to position Amplia for the future by building a more sophisticated and scalable company. Under the direction of a highly credentialed Board, the Company is underpinned by a culture of innovation and excellence – with planning and preparation, both cornerstones of its success. 2022 represented a year of increased activity for Amplia as it progressed its Phase 1b/2a ACCENT trial in pancreatic cancer. Considered forwardplanning was a crucial part of this, enabling the team to establish strong working relationships with key opinion leading (KOL) doctors and their patients, to effectively recruit for, and implement the clinical The Amplia team is highly motivated, with deep and varied expertise. The Company has assembled talented individuals with diverse backgrounds and skills across all areas of operations, from the lab bench to the clinic. Its in-house credentials are bolstered by a network of trusted specialist advisors too. program. Targeted activities to amplify awareness of, and engagement with, the trial has also been successful. In early 2023, the Amplia team ran a strategic planning workshop to reflect on the Company’s strengths, to identify new opportunities, and set priorities for the future that are aligned with clear values and purpose – a regular checkpoint, as the Company grows and nurtures a high-achieving culture along the way. Streamlining Operations Amplia is futureproofing its operations by investing in the improvement of systems and processes, including in areas of project management, cyber-security and quality systems. Growing The Team Building a worldclass team is critical to achieving Amplia’s mission, so recruiting and supporting an appropriately skilled workforce has been a primary focus of FY22-23. In particular, the Quality Management System (QMS) framework will enable the team to manage drug 13 development processes, from early research to clinical trials and commercialisation. The integration of a QMS into Amplia’s operations will help to improve efficiencies, ensure compliance with regulatory requirements, and maintain the highest standards of quality across all activities. ESG In line with Amplia’s values-driven approach, the Company is currently exploring ways to incorporate ESG (Environment, Society, Governance) initiatives into its operations. By adopting a more sustainable and socially responsible approach to business, Amplia will create long-term value for its valued stakeholders and positively impact the communities it serves. Clinical trials bright minds, steady hands Clinical trials are a crucial step in the development of new medical treatments - but it’s no secret they are complex and demanding, with strict regulatory requirements, ethical standards, and safety guidelines. Recruiting experienced and steady hands to guide the process is vital, which is exactly what we have done at Amplia. The launch of Amplia’s ACCENT trial in 2022 was the culmination of rigorous planning and collaboration, and signalled a critical milestone in the development of AMP945. Amplia’s team of experienced clinical trial experts have been integral to its success, leveraging specialist expertise every step of the way. “Initiating a Phase 2 clinical trial requires an immense breadth of knowledge of the operational, regulatory and logistical elements of clinical trial development. Fortunately, Amplia has assembled an exceptional team of employees and collaborators dedicated to ensuring that not only are there no gaps in the science, but that the clinical development process runs as smoothly and successfully as possible,” explains Amplia’s CEO and MD, Dr Chris Burns. With regulatory approval and commercialisation the ultimate goals, Amplia must maintain meticulous documentation of the entire clinical development journey. This is an administrative responsibility that is not only required for regulatory compliance, but also safeguards the Company in the event of staffing changes during the course of the clinical development process. Amplia’s Clinical Operations Manager, Nicole Kruger, is no stranger to the complexities of managing clinical research programs. Nicole has been working in the biotechnology and pharmaceutical sector for three decades, helping biotechnology companies to implement and manage their clinical research programs and projects. While planning a clinical trial, and its many moving parts can sound onerous, Nicole says Amplia’s rigorous processes, including their approach to record-keeping combined with a specialist team and experienced trial sites, helped to streamline the commencement of the ACCENT trial. “It can be complex, but not difficult,” she explained. “The team has worked closely with each of the clinical trial sites who conduct the trials, to bring together all the necessary documentation and procedures required to ensure that our clinical protocols are ethical and scientifically sound,” said Nicole. Nicole’s knowledge and understanding of the regulatory and governance frameworks that underpin the clinical trials process means that the ACCENT trial remains on track, meeting all necessary checkpoints as they arise during the trial. As Amplia nears Stage 2 of the trial, preparations are ongoing to ensure that the clinical trial program continues to meet both clinical and regulatory milestones – on time, and on budget. “There is a responsibility, as the trial Sponsor, to ensure that we meet our legal and ethical responsibilities, and that patient wellbeing remains at the heart of our clinical program,” said Dr Burns. “We are very fortunate to be able to lean on a dynamic and highly-focused team that understands the work that needs to be done, can navigate the challenges, and believes in our vision to help bring more effective treatments to pancreatic cancer patients”. 14 Relationship building, the secret to trial recruitment Establishing a transparent, supportive and productive working relationship with the trial sites is vital to support successful recruitment to a clinical trial. “Clinical development is as much about logistics and relationship-building as it is about the science,” explains Amplia’s Principal Development Manager, Anthony Bishop. “Once the trial protocol is agreed and approved, we work closely with the sites to maintain clear, open and timely communication of all data and developments as they arise.” Anthony works closely with the trial sites to make sure the recruitment process is smooth, with a steady stream of patients moving through. Each site has a clinical trial coordinator who interfaces with the patients, and Amplia meets regularly with them to ensure that the site has all the necessary information and documentation in place to recruit patients. With over 25 years in pharmaceutical development, Anthony has been involved in many clinicals trials – from both the sponsor and the CRO perspective. “ There are many moving parts and resources that need to come together, and sensitively navigating the challenges for both is definitely an advantage to keep things moving forward.” Now recruiting The ACCENT Phase 2 clinical trial is now recruiting people who have been diagnosed with advanced pancreatic cancer, specifically those patients who have inoperable pancreatic cancer or whose cancer has spread to other parts of the body. Patients will be initially recruited through treating doctors at hospitals in Melbourne, Sydney, and Brisbane. In total, it is expected that the trial will recruit approximately 62 participants. Learn more: ampliatx.com/accent News Flow and Milestones Media Headlines The launch of Amplia’s ACCENT trial attracted attention from top-tier media outlets and industry publications. This coverage highlights Amplia’s growing reputation and recognition as a pioneering force in the biotechnology industry. Trial launch makes national headlines In partnership with research collaborators at the Garvan Institute of Medical Research, Amplia launched a media campaign to support recruitment of pancreatic cancer patients for the ACCENT clinical trial. The media campaign initially made national headlines with a page 3 feature in The Australian, by Health Editor Natasha Robinson. The article, titled ‘Drug to tear down pancreatic tumour defences’ explained the importance of Amplia’s research, and the novel treatment capabilities of FAK inhibitor, AMP945. The drug, AMP945, has the potential to make chemotherapy much more effective because it breaks down a fibrous shield that surrounds cancer cells that makes them difficult to penetrate. The trial was also featured on prime-time television, with Channel 9’s Health Reporter, Gabriella Rogers, meeting with Amplia’s former CEO, Dr John Lambert, and Garvan Institute’s, Professor Paul Timpson, to discuss Amplia’s Phase1b/2a clinical trial of AMP945 in people with pancreatic cancer. 16 Northern Exposure: Queensland media embraces ACCENT trial In February 2023, Amplia opened a trial site in Queensland, bringing the total number of clinical trial sites to seven across Melbourne, Sydney and Brisbane. The announcement attracted significant coverage across television, print and radio. Channel 9 News filmed an interview with clinical trial investigator at Greenslopes Private Hospital, Dr Warren Joubert. The segment also featured pancreatic cancer patient, Judi Adams, who bravely shared her own experience with the disease – together with a passionate plea encouraging patient participation in medical research. Courier Mail Health Reporter, Jackie Sinnerton, published an article titled “New hope for advanced pancreatic cancer patients in clinical trials,” highlighting the importance of new therapies in the face of grim survival statistics for patients. Amplia CEO and MD, Dr Chris Burns, also spoke with Craig Zonca and Loretta Ryan on ABC Radio Brisbane Breakfast to discuss the details of the trial, and how patients could get involved. ASX announcements April 2022 Amplia Receives Ethics Clearance for Phase 2 Trial in Pancreatic Cancer Patients May 2022 Amplia Receives Second Ethics Clearance for Phase 2 Trial June 2022 AMP945 Shows Efficacy in Model of Lung Fibrosis August 2022 First Patient Recruited to ACCENT Trial in Pancreatic Cancer August 2022 Amplia receives $1.8m R&D Tax Incentive September 2022 American Association for Cancer Research (AACR) Conference Presentation October 2022 AMP886 Activity in Acute Myeloid Leukemia (AML) November 2022 Amplia appoints Dr Christopher Burns as CEO and Managing Director November 2022 Enrolment of the first cohort of patients into ACCENT Trial completed November 2022 Dose Escalation Approved in ACCENT Clinical Trial of AMP945 January 2023 First Patient Recruited to Cohort 2 of ACCENT Trial in Pancreatic Cancer February 2023 ACCENT clinical trial presentation at the 35th Annual Lorne Cancer Conference February 2023 Amplia’s FAK inhibitor program presented at Next Generation Kinase Inhibitors Summit in Boston, USA Enrolment of the second cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial completed February 2023 17 Q&A with Dr Chris Burns, CEO & MD An experienced leader with over 25 years in drug discovery and development, Dr Chris Burns co-founded Amplia Therapeutics in 2016. He has been a Director on the Amplia Board since 2018, and in December 2022, was appointed as Chief Executive Officer and Managing Director. Tell us about your background and how you came to be the CEO of Amplia Therapeutics? I have worked in drug discovery and development for most of my professional career. In 2016, a group of like-minded drug developers got together in Melbourne and together we founded Amplia, with the goal of developing the FAK inhibitors discovered at the Cancer Therapeutics CRC. Once we had secured the IP, we set about building and financing the Company, ultimately settling on reverse-listing onto the ASX in 2018. I became a Director of the Company at that time and have worked closely with the other Board members and management to help progress the development of the FAK assets. In late 2022, Dr John Lambert announced his retirement and I stepped into the CEO role in December 2022. What are the core values and mission of Amplia Therapeutics, and how do they guide the Company’s direction? Our core values of Patient Focus, Integrity, Respect, Performance, Innovation, Accountability and Excellence succinctly describe our approach to our mission of developi